Evidence map›Paper›PMID 39382001›Full record

Trial reportDiabetes, obesity & metabolism2025

Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod® 5 Automated Insulin Delivery System.

Georgia M Davis, Anne L Peters, Bruce W Bode, Anders L Carlson, Bonnie Dumais, Todd E Vienneau, Lauren M Huyett, Trang T Ly

Abstract readMulticenter StudyClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Registration and Real-Life Studies on Automated Insulin Delivery Systems.Journal of diabetes science and technology · 2025
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Georgia M DavisDepartment of Medicine, Division of Endocrinology, Metabolism and Lipids, Emory University, Atlanta, Georgia, USA.
Anne L PetersKeck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID 0000-0003-0520-0776
Bruce W BodeAtlanta Diabetes Associates, Atlanta, Georgia, USA.
Anders L CarlsonInternational Diabetes Center, Park Nicollet, HealthPartners, Minneapolis, Minnesota, USA.
Bonnie DumaisInsulet Corporation, Acton, Massachusetts, USA.
Todd E VienneauInsulet Corporation, Acton, Massachusetts, USA.
Lauren M HuyettInsulet Corporation, Acton, Massachusetts, USA.
Trang T LyInsulet Corporation, Acton, Massachusetts, USA.ORCID 0000-0002-5995-1447

Funding

New York Regional Center for Diabetes Translation ResearchP30DK111022 · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2025 to 2025
$810k
Insulet CorporationNIDDK NIH HHS P30 DK111022
6 · The paper itself

Abstract

aimsThe aim was to evaluate the effect of extended use of the Omnipod® 5 Automated Insulin Delivery (AID) System in adults with type 2 diabetes and suboptimal glycaemic control. MATERIALS AND

methodsFollowing an 8-week single-arm, multicentre, outpatient trial of AID in adults with type 2 diabetes and baseline HbA1c ≥ 8% (≥ 64 mmol/mol), participants were given the opportunity to continue use of the AID system in a 26-week (~6 month) extension phase. The primary safety endpoints were percentage of time with sensor glucose ≥ 250 mg/dL and < 54 mg/dL. Additional glycaemic measures, including percentage of time in range (TIR) (70-180 mg/dL) and HbA1c, were evaluated. The use of non-insulin anti-hyperglycaemic medications was permitted throughout the entire study.

resultsDuring the initial 8-week study, participants (N = 22) achieved a decrease in percentage of time ≥ 250 mg/dL from 27.4% ± 21.0% to 10.5% ± 8.8% (p < 0.0001), which further decreased to 9.7% ± 9.2% during the extension phase (p = 0.0002 vs. standard therapy). Percentage of time < 54 mg/dL remained low from standard therapy through extension (median [interquartile range] 0.00% [0.00%, 0.06%] vs. 0.02% [0.00%, 0.05%], p > 0.05). HbA1c decreased by 1.6% ± 1.2% (15.5 ± 13.1 mmol/mol, p < 0.0001) and TIR increased by 22.4% ± 19.2% (p < 0.0001) from standard therapy through extension with no significant change in body mass index and without an observed increase in total daily insulin requirements.

conclusionsThese longer-term findings of Omnipod 5 AID System use demonstrate the potential value of AID in helping people with type 2 diabetes reach glycaemic targets.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Glycated HemoglobinGlycemic ControlHypoglycemic AgentsInsulinInsulin Infusion SystemsAdultAgedBlood Glucose Self-MonitoringFemaleHumansMaleMiddle AgedTreatment OutcomeBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinclinical trialGLP‐1insulin pump therapySGLT‐2 inhibitortype 2 diabetes

Identifiers

PMID39382001
PMCPMC11618232

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.